论文部分内容阅读
目的:总结经尿道膀胱肿瘤电切(TUR-BT)术后辅以沙培林(注射用A群链球菌)联合丝裂霉素(MMC)膀胱内灌注治疗高危膀胱癌的疗效。方法:回顾性研究2009年1月~2012年8月我院收治的符合高危非肌层浸润性膀胱癌患64例,观察组:TUR-BT术后行沙培林联合MMC膀胱内灌注化疗32例,对照组;MMC单药灌注32例。结果:观察组患者,平均年龄63.7岁,治疗随访时间为6~54个月,中位时间27.3个月。治疗随访期间有3例患者出现膀胱内肿瘤复发(9.3%),1例患者疾病进展,发展为肌层浸润性膀胱癌,于术后7个月死亡(3.1%)。与对照组患者相比,疾病复发率及进展率均明显改善。结论:高危非肌层浸润膀胱癌临床复发率、进展率高,TUR-BT术后沙培林联合MMC膀胱内灌注通过局部化疗及免疫治疗联合,可有效控制疾病的复发和进展,降低患者接受膀胱部分切除或膀胱全切手术的机率,值得推广。
Objective: To summarize the curative effect of transurethral resection of bladder tumor (TUR-BT) combined with intraperitoneal perfusion of sapirin (group A Streptococcus injection) and mitomycin (MMC) in the treatment of high-risk bladder cancer. Methods: A retrospective study of 64 patients with high-risk non-muscle invasive bladder cancer treated in our hospital from January 2009 to August 2012 was performed. Patients in the observation group were treated with TUR-BT followed by intravesical chemotherapy with sapirin and MMC Cases, control group; MMC single drug perfusion in 32 cases. Results: The observation group patients, mean age 63.7 years, treatment follow-up time was 6 to 54 months, the median time was 27.3 months. Three patients developed intravesical tumor recurrence (9.3%) during treatment follow-up. One patient developed disease that developed muscle-invasive bladder cancer and died at 7 months (3.1%). Compared with the control group, the disease recurrence rate and progression rate were significantly improved. Conclusions: The high-risk non-muscle invasion of bladder cancer clinical recurrence rate, high rate of progression, TUR-BT postoperative cisplatin and MMC intravesical instillation through local chemotherapy and immunotherapy combined can effectively control the recurrence and progression of the disease, reduce the patient’s acceptance Bladder partial resection or the chance of total bladder resection surgery, it is worth promoting.